BCM
AQST icon

Bayesian Capital Management’s Aquestive Therapeutics AQST Stock Holding History

Bayesian Capital Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-19,700
Closed -$98.1K – 682
2024
Q3 		$98.1K Buy
+19,700
New +$76.7K 0.01% 605
2022
Q4 		– Sell
-10,235
Closed -$12K – 770
2022
Q3 		$12K Buy
+10,235
New +$11.6K ﹤0.01% 650

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Bayesian Capital Management's AQST Position: Q4 2024 in Review

Bayesian Capital Management sold out of Aquestive Therapeutics (AQST) in Q4 2024, closing a stake of 19,700 shares — an estimated $98.1K sold.

Bayesian Capital Management first reported a position in AQST in Q3 2022 and held it in 2 quarters. The position peaked at $98.1K in Q3 2024. 114 funds tracked by Wall St. Rank hold AQST as of Q4 2024.

  • Bayesian Capital Management reported no remaining Aquestive Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 19,700 Aquestive Therapeutics shares in Q4 2024, an estimated $98.1K.
  • Bayesian Capital Management first reported a position in Aquestive Therapeutics in Q3 2022 and held it in 2 quarters.
  • Bayesian Capital Management's Aquestive Therapeutics position peaked at $98.1K in Q3 2024.
  • 114 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q4 2024.

Based on Bayesian Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.